{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:36Z","timestamp":1793142756177,"version":"4.5.0"},"reference-count":85,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhibition of Bruton\u2019s tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-\u03baB. Clinically, because indefinite inhibition is a mainstay of therapy, there is an extended period of exposure in which adverse effects can develop. Given the impressive efficacy and activity of BTKis in the treatment of patients with CLL, appropriate management of treatment-emergent adverse events (AEs) is of paramount importance. Here we review the BTKi landscape and present the available toxicity and safety data for each agent. The long-term toxicity profile of ibrutinib, a first-in-class inhibitor, is well characterized and includes a clinically significant incidence of cardiac arrhythmias, bleeding, infection, diarrhea, arthralgias, and hypertension. Acalabrutinib, the initial second-generation BTKi to earn approval from the US Food and Drug Administration, demonstrates improved kinase selectivity for BTK, with commonly observed adverse reactions including infection, headache, and diarrhea. Mediated by both on-target inhibition of BTK and variable off-target inhibition of other kinases including interleukin-2\u2013inducible T-cell kinase (ITK), tyrosine-protein kinase (TEC), and endothelial growth factor receptor (EGFR), the toxicity profile of BTKis is closely linked to their pattern of kinase binding. Other emerging BTKis include second-generation agents with variable degrees of kinase selectivity and third-generation agents that exhibit reversible noncovalent binding to BTK. We also highlight critical considerations for the prevention and monitoring of AEs and offer practical management strategies for treatment-emergent toxicities.<\/jats:p>","DOI":"10.1182\/hematology.2020000118","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:10:40Z","timestamp":1607137840000},"page":"336-345","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":164,"title":["Managing toxicities of Bruton tyrosine kinase inhibitors"],"prefix":"10.1182","volume":"2020","author":[{"given":"Andrew","family":"Lipsky","sequence":"first","affiliation":[{"name":"Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2020121621165783000_B1","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2020121621165783000_B2","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Herman","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"2020121621165783000_B3","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020121621165783000_B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2020121621165783000_B5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2020121621165783000_B6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"2020121621165783000_B7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020121621165783000_B8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2020121621165783000_B9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"10232","key":"2020121621165783000_B10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"2020121621165783000_B11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621165783000_B12","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2020.38.15_suppl.8015","article-title":"Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): ASCEND final results","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020121621165783000_B13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V128.22.642.642","article-title":"Twice daily dosing with the highly specific BTK inhibitor, Bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"128","author":"Tam","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621165783000_B14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2019-125394","article-title":"Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621165783000_B15","doi-asserted-by":"crossref","first-page":"TPS7572","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7572","article-title":"ALPINE: phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020121621165783000_B16","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","article-title":"Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia","volume":"26","author":"Danilov","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2020121621165783000_B17","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood.V128.22.2032.2032","article-title":"First-in-human phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of the noncovalent Bruton tyrosine kinase (BTK) inhibitor SNS-062 in healthy subjects","volume":"128","author":"Neuman","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020121621165783000_B18","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"2020121621165783000_B19","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.clml.2018.07.081","article-title":"LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors","volume":"18","author":"Brandhuber","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2020121621165783000_B20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"2020121621165783000_B21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"29","key":"2020121621165783000_B22","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2020121621165783000_B23","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020121621165783000_B24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621165783000_B25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2019-125483","article-title":"Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): updated results from a phase 1\/2 trial","volume":"134","author":"Cull","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2020121621165783000_B26","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","article-title":"Long-term follow-up of patients with CLL treated with the selective Bruton\u2019s tyrosine kinase inhibitor ONO\/GS-4059","volume":"129","author":"Walter","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020121621165783000_B27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020121621165783000_B28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020121621165783000_B29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fonc.2020.00894","article-title":"Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents","volume":"10","author":"Sedlarikova","year":"2020","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2020121621165783000_B30","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2019-126286","article-title":"Ongoing results of a phase 1B\/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton\u2019s tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies","volume":"134","author":"Allan","year":"2019","journal-title":"Blood"},{"key":"2020121621165783000_B31","unstructured":"GlobeNewswire Press release. Sunesis Pharmaceuticals announces clinical update on vecabrutinib program. 2020; https:\/\/www.globenewswire.com\/news-release\/2020\/06\/23\/2051898\/0\/en\/Sunesis-Pharmaceuticals-Announces-Clinical-Update-on-Vecabrutinib-Program.html. Accessed August 1, 2020."},{"issue":"suppl 1","key":"2020121621165783000_B32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2019-127509","article-title":"Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, noncovalent BTK inhibitor","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2020121621165783000_B33","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"issue":"suppl 1","key":"2020121621165783000_B34","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020121621165783000_B35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2020121621165783000_B36","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1161\/01.CIR.96.7.2455","article-title":"Incidence of and risk factors for atrial fibrillation in older adults","volume":"96","author":"Psaty","year":"1997","journal-title":"Circulation"},{"issue":"7","key":"2020121621165783000_B37","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2020121621165783000_B38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O\u2019Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2020121621165783000_B39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2020121621165783000_B40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2019-126824","article-title":"Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 Trial","volume":"134","author":"Shanafelt","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621165783000_B41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2018-99-116653","article-title":"Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202","volume":"132","author":"Woyach","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2020121621165783000_B42","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020121621165783000_B43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020121621165783000_B44","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020121621165783000_B45","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"2020121621165783000_B46","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2020121621165783000_B47","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020121621165783000_B48","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2020121621165783000_B49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2020121621165783000_B50","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2015.140558","article-title":"Response to comment on incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"101","author":"Lipsky","year":"2016","journal-title":"Haematologica"},{"issue":"24","key":"2020121621165783000_B51","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","article-title":"Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans","volume":"3","author":"Dobie","year":"2019","journal-title":"Blood Adv"},{"issue":"15","key":"2020121621165783000_B52","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2020121621165783000_B53","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","article-title":"Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages","volume":"100","author":"Borge","year":"2015","journal-title":"Haematologica"},{"issue":"18","key":"2020121621165783000_B54","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020121621165783000_B55","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3324\/haematol.2019.219220","article-title":"Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus","volume":"105","author":"Blez","year":"2020","journal-title":"Haematologica"},{"key":"2020121621165783000_B56","article-title":"Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors [published online ahead of print 6 June 2020]","author":"Pleyer","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2020121621165783000_B57","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2020121621165783000_B58","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2020121621165783000_B59","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020121621165783000_B60","article-title":"Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib [published online ahead of print 12 June 2020]","author":"Frei","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2020121621165783000_B61","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"2020121621165783000_B62","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.blre.2019.100635","article-title":"Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections","volume":"40","author":"Maffei","year":"2020","journal-title":"Blood Rev"},{"issue":"suppl 1","key":"2020121621165783000_B63","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2019-121675","article-title":"Response to the Shingrix varicella zoster virus (VZV) vaccine in patients with chronic lymphocytic leukemia (CLL) that are treatment naive or treated with a Bruton\u2019s tyrosine kinase inhibitor (BTK-I)","volume":"134","author":"Pleyer","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2020121621165783000_B64","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter, international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2020121621165783000_B65","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1097\/HS9.0000000000000432","article-title":"How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic","volume":"4","author":"Rossi","year":"2020","journal-title":"HemaSphere"},{"key":"2020121621165783000_B66","unstructured":"Shadman\n              M\n            , ByrdJ, HallekM, et al. COVID-19 and CLL: frequently asked questions (version 3.0). 2020; https:\/\/www.hematology.org\/covid-19\/covid-19-and-cll. Accessed August 1, 2020."},{"issue":"22","key":"2020121621165783000_B67","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621165783000_B68","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1200\/JCO.2020.38.15_suppl.8024","article-title":"Acalabrutinib in treatment-na\u00efve chronic lymphocytic leukemia: mature results from phase II study demonstrating durable remissions and long-term tolerability","volume":"38","author":"Byrd","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020121621165783000_B69","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clml.2020.02.001","article-title":"Ibrutinib-associated arthralgias\/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes","volume":"20","author":"Rhodes","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"2020121621165783000_B70","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance","volume":"116","author":"Moreno","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020121621165783000_B71","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2020121621165783000_B72","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.3324\/haematol.2015.138289","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"101","author":"Vitale","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2020121621165783000_B73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.15545","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre","volume":"183","author":"Hampel","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2020121621165783000_B74","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2020121621165783000_B75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management","volume":"180","author":"Iberri","year":"2018","journal-title":"Br J Haematol"},{"key":"2020121621165783000_B76","article-title":"Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors [published online ahead of print 1 July 2020]","author":"Sibaud","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"2020121621165783000_B77","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2016.0225","article-title":"Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia","volume":"152","author":"Bitar","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"19","key":"2020121621165783000_B78","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020121621165783000_B79","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"2020121621165783000_B80","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.2019896688","article-title":"Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL","volume":"133","author":"Ahn","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2020121621165783000_B81","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"2020121621165783000_B82","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2020121621165783000_B83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2020121621165783000_B84","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"18","author":"Barrientos","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020121621165783000_B85","first-page":"LB2606","article-title":"ASCEND phase 3 study of acalabrutinib vs investigator\u2019s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) [abstract]","author":"Ghia","year":"2019","journal-title":"EHA Lib"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/336\/1794927\/hem2020000118c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/336\/1794927\/hem2020000118c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:13:28Z","timestamp":1608315208000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/336\/474309\/Managing-toxicities-of-Bruton-tyrosine-kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000118","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}